Batch 001 - Live Allocation
3/100 SoldQ4 launch pricing · ends 31 Dec
VL
Vivre Labs
Institutional Longevity
- Peptides -
- Single-vial Blends -
- Goals -
- Clinical Reference -
- Guides -
- Integrity -

◇ Compound Reference

IMMUNOMODULATORApproved (Intl)Popular · Immune Support

Thymosin Alpha-1

Immune Regulator · 10mg

Status
Approved (Intl)
Route
SubQ
Half-life
~2 hours plasma
Class
Thymic peptide
MechanismT-Cell Maturation & Activation
Cohort61 active prescriptions
Educational reference only - not a prescription or dosing recommendation. Some compounds are investigational or used off-label; suitability is a question for your own doctor. See Informed Consent & Disclaimer.
V-Series Member
$75.05 USD/vial
À-la-carte: $79 USD/vial · Save 5%
Q4 launch pricing until 31 Dec · regular $88 USD/vial from 1 Jan
Vials per allocation
Member total (1×)$75.05
À-la-carte total$79
Flat per-vial pricing. International shipping $35, free on orders of $250 or more.
What this is

Immune system regulator supporting T-cell function and innate immunity. Applications in chronic infection and immunosenescence.

Immune Regulator · 10mg per vial · lot-tested.

◇
Janoshik Verified
HPLC + MS purity, every batch
Independent third-party lab
⬡
COA Per Batch
Lot-level certificates published
Labeled vs actual mg disclosed
⊙
Lot-Tested
Every lot, independent lab
Report and verification code per lot
Thymosin Alpha-1 · Immunomodulator
◆ Certificate of Analysis · Thymosin Alpha-1
JANOSHIK ANALYTICALHPLC + MS · Independent third-party
Lot testing in progress. The independent lab report for this Thymosin Alpha-1 lot will be published here, with its verification code, as soon as it is back.
◉
Clinical Overview
Thymosin Alpha-1

Thymosin Alpha-1 is a 28-amino-acid peptide hormone naturally produced by the thymus gland. Approved for clinical use in over 35 countries (notably for chronic hepatitis B and C, and as adjunct cancer therapy).

Acts as a key immune system regulator.

◈
Immune Modulation
Modulates T-cell maturation and innate immunity.
❖
Immune Balance
Increases helper T-cell and NK-cell activity.
✦
Approval Abroad
Approved in some countries; off-label in the US.
◈
Mechanism
How It Works

Modulates T-cell maturation, dendritic cell function, and innate immunity. Increases helper T-cell production and Natural Killer cell activity.

Particularly relevant in age-related immune decline (immunosenescence).

Mechanism & evidence - the honest frame
Mechanism & evidence: Thymosin alpha-1 (thymalfasin; historically marketed as Zadaxin) is an immunomodulator that promotes T-cell maturation, enhances regulatory T-cells and balances Th1/Th17 responses, acting partly through dendritic-cell signalling. Strongest oncology signal is a phase-2 setting: adding Tα1 to dacarbazine in stage-IV melanoma produced more confirmed responses than chemotherapy alone (Maio et al., J Clin Oncol 2010) - a positive phase-2 signal in small numbers, not a practice-changing phase-3 result. Approved abroad as an adjuvant in hepatitis B/C and certain cancers; US availability is off-label. Sepsis/infectious-disease data remain mixed.
✚
Patient Bloodwork Guide
Bloodwork for Recovery & Repair Protocols

Tissue repair / anti-inflammatory - BPC-157, TB-500, KPV, Thymosin, V-01, V-05

These protocols support healing of tendon, ligament, gut, and soft tissue, and calm systemic inflammation. Monitoring tracks inflammation coming down and confirms the body is recovering rather than being strained.

Incremental approach. Vivre uses conservative, course-based dosing - often a defined repair window rather than indefinite use. Markers and imaging confirm progress before extending.

Inflammation
hs-CRPA sensitive marker of systemic inflammation - the key “is it calming down” signal.
IL-6An inflammatory messenger; tracked alongside hs-CRP.
ESRA classic inflammation marker for the bigger picture.
Healing confirmation
Imaging (ultrasound)For tendon/ligament work - confirms structural healing, not just how you feel.
Immune markers (CD4/CD8)Where immune modulation (e.g. Thymosin) is part of the protocol.
Overall safety
CBC & CMPStandard blood count, liver, and kidney panels.
When the tests happen
Baselinehs-CRP, IL-6, ESR + imaging of the target area.
Weeks 4 / 8 / 12hs-CRP, IL-6, ESR - track inflammation trend.
Week 12Repeat imaging to confirm structural healing.

Educational only - not medical advice or a dosing instruction. Your own doctor orders tests, interprets results and decides what is right for you. See the Informed Consent & Disclaimer for full terms.

⊞
Technical Profile
Measurable Properties
ClassThymosin α1 (28 aa immunomodulatory peptide)
MechanismT-cell function modulation; innate/adaptive immune signalling - characterised
Terminal half-lifeShort (~2 hours order)
MetabolismPeptidase degradation
Evidence baseModerate-to-strong; approved for certain indications in some jurisdictions
Regulatory statusApproved in some markets for specific uses; otherwise research use only
Certificate of Analysis (per batch)
Analytical method: UHPLC-MS. Batch COA available on request - link to be populated per shipment.
COA link - pending per batch
Immunopharmacology reasonably characterised; approval varies by market. Educational only.
§
Clinical Literature
Peer-Reviewed References

Thymosin Alpha-1: A Comprehensive Review of the Literature

King R, Tuthill C · 2016 · International Immunopharmacology 2016;33:9–14
▾

Findings

Review of clinical and mechanistic literature on Thymosin alpha-1, summarising trial data across chronic hepatitis, vaccine adjuvant use, and immune-modulating contexts. The compound is approved in multiple jurisdictions for specific indications; broad anti-aging or general-immunity claims outside those indications are not supported by the controlled trial evidence.

View on publisher ↗
Thymosin alpha-1 has trial-supported approvals for specific indications in some markets. Use beyond approved indications is off-label.
◇
Clinical Applications
Indications
  • Chronic viral infection adjunct
  • Immunosenescence
  • Cancer therapy adjunct (with oncologist oversight)
  • Chronic immune dysregulation
⊙
Pharmacokinetics
Half-Life & Duration of Action
Half-life is how long a compound stays at active plasma concentration in your body. Most peptides in this catalogue have short plasma half-lives - they clear from your bloodstream within hours, sometimes minutes. The long-half-life compounds in this catalogue are the approved-class incretins (Tirzepatide, Semaglutide, Retatrutide), which are designed for once-weekly dosing - that's the molecular engineering choice that makes weekly dosing work.
Plasma Half-Life
~2 hours plasma. Immune-modulating effects on T-cell and innate immune function persist longer through downstream immunological signaling.
Why this matters for you
If you don't tolerate a compound or need to discontinue a protocol, short-half-life peptides are out of your bloodstream within hours - not days or weeks. That said, the biological effects they initiate (tissue repair signalling, mitochondrial signalling, gene expression changes) often persist longer than the peptide itself, through downstream cellular cascades. This is normal peptide pharmacology and is important context - the molecule clears fast, but the biology takes longer to wind down.
Evidence Base
Approved in many countries. Established clinical safety profile. Limited US FDA approval but available through compounding.
Dosing protocols, administration frequency, and titration schedules are not published on these public pages.
▣
Featured In
V-Series Protocols Including Thymosin Alpha-1
◎
Commonly Paired
Compounds Often Paired With Thymosin Alpha-1
Clinical co-allocation patterns observed in Vivre's allocation history. Pairings are not prescriptions.
Cytoprotective Peptide
BPC-157
Base Form · 5mg
◆ immune + repair
Thymosin α1's immune-modulating activity pairs with BPC-157's regenerative signal in protocols where immunological dysregulation underlies impaired healing.
View BPC-157 detail →
FOR CUSTOMERS

Mixing guide and dosage calculator

Unlocks once you order Thymosin Alpha-1: step-by-step mixing with illustrations, storage, and a calculator that converts any dose to syringe units at your vial strength.

READY TO PROCEED

Start with the Biological Audit

Thymosin Alpha-1 is verified and lot-tested, dispensed following a Biological Audit. The Audit is complimentary for the Batch 001 cohort.

$75.05 USD/vial
Thymosin Alpha-1 · Member rate
VL
Vivre Labs
Institutional Longevity

Peptides and blends with independently tested lots, published lot by lot. Research use only.

V-Series

Peptides

Metabolic
Repair & Aesthetic
Neurological
Growth & Hormonal
Longevity & Immune
Sexual Health

Navigate

Verification

Products are sold for research use only and are not intended to diagnose, treat, cure or prevent any disease. Content on this site is educational and is not medical advice. Lot results apply to the lot tested; see each report for details. For adults 21 and over.

© 2026 Vivre Labs. All rights reserved.

Lot-TestedJanoshik-Verified